Liver transplantation for malignancy:current treatment strategies and future perspectives
|
摘要
In 1967,Starzl et al performed the first successful liver transplantation for a patient diagnosed with hepatoblastoma.In the following,liver transplantation was considered ideal for complete tumor resection and potential cure from primary hepatic malignancies.Several reports of liver transplantation for primary and metastatic liver cancer however showed disappointing results and the strategy was soon dismissed.In1996,Mazzaferro et al introduced the Milan criteria,offering liver transplantation to patients diagnosed with limited hepatocellular carcinoma.Since then,liver transplantation for malignant disease is an ongoing subject of preclinical and clinical research.In this context,several aspects must be considered:(1)Given the shortage of deceased-donor organs,long-term overall and disease free survival should be comparable with results obtained in patients transplanted for nonmalignant disease;(2)In this regard,living-donor liver transplantation may in selected patients help to solve the ethical dilemma of optimal individual patient treatment vs organ allocation justice;and(3)Ongoing research focusing on perioperative therapy and antiproliferative immunosuppressive regimens may further reduce tumor recurrence in patients transplanted for malignant disease and thus improve overall survival.The present review gives an overview of current indications and future perspectives of liver transplantation for malignant disease.
In 1967,Starzl et al performed the first successful liver transplantation for a patient diagnosed with hepatoblastoma.In the following,liver transplantation was considered ideal for complete tumor resection and potential cure from primary hepatic malignancies.Several reports of liver transplantation for primary and metastatic liver cancer however showed disappointing results and the strategy was soon dismissed.In 1996,Mazzaferro et al introduced the Milan criteria,offering liver transplantation to patients diagnosed with limited hepatocellular carcinoma.Since then,liver transplantation for malignant disease is an ongoing subject of preclinical and clinical research.In this context,several aspects must be considered:(1) Given the shortage of deceased-donor organs,long-term overall and disease free survival should be comparable with results obtained in patients transplanted for nonmalignant disease;(2) In this regard,living-donor liver transplantation may in selected patients help to solve the ethical dilemma of optimal individual patient treatment vs organ allocation justice; and(3) Ongoing research focusing on perioperative therapy and antiproliferative immunosuppressive regimens may further reduce tumor recurrence in patients transplanted for malignant disease and thus improve overall survival.The present review gives an overview of current indications and future perspectives of liver transplantation for malignant disease.
In 1967,Starzl et al performed the first successful liver transplantation for a patient diagnosed with hepatoblastoma.In the following,liver transplantation was considered ideal for complete tumor resection and potential cure from primary hepatic malignancies.Several reports of liver transplantation for primary and metastatic liver cancer however showed disappointing results and the strategy was soon dismissed.In 1996,Mazzaferro et al introduced the Milan criteria,offering liver transplantation to patients diagnosed with limited hepatocellular carcinoma.Since then,liver transplantation for malignant disease is an ongoing subject of preclinical and clinical research.In this context,several aspects must be considered:(1) Given the shortage of deceased-donor organs,long-term overall and disease free survival should be comparable with results obtained in patients transplanted for nonmalignant disease;(2) In this regard,living-donor liver transplantation may in selected patients help to solve the ethical dilemma of optimal individual patient treatment vs organ allocation justice; and(3) Ongoing research focusing on perioperative therapy and antiproliferative immunosuppressive regimens may further reduce tumor recurrence in patients transplanted for malignant disease and thus improve overall survival.The present review gives an overview of current indications and future perspectives of liver transplantation for malignant disease.
引文
1 Kim WR,Stock PG,Smith JM,Heimbach JK,Skeans MA,Edwards EB,Harper AM,Snyder JJ,Israni AK,Kasiske BL.OPTN/SRTR 2011 Annual Data Report:liver.Am J Transplant 2013;13Suppl 1:73-102[PMID:23237697 DOI:10.1111/ajt.12021]
2 Jones PD,Hayashi PH,Barritt S.Liver transplantation in2013:challenges and controversies.Minerva Gastroenterol Dietol 2013;59:117-131[PMID:23831904]
3 Kim WR,Therneau TM,Benson JT,Kremers WK,Rosen CB,Gores GJ,Dickson ER.Deaths on the liver transplant waiting list:an analysis of competing risks.Hepatology 2006;43:345 -351[PMID:16440361 DOI:10.1002/hep.21025]
4 Malinchoc M,Kamath PS,Gordon FD,Peine CJ,Rank J,ter Borg PC.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.Hepatology 2000;31:864-871[PMID:10733541 DOI:10.1053/he.2000.5852]
5 Said A,Williams J,Holden J,Remington P,Gangnon R,Musat A,Lucey MR.Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease.J Hepatol 2004;40:897-903[PMID:15158328 DOI:10.1016/j.jhep.2004.02.010]
6 Weismüller TJ,Negm A,Becker T,Barg-Hock H,Klempnauer J,Manns MP,Strassburg CP.The introduction ofMELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics.Transpl Int 2009;22:970-978[PMID:19619170DOI:10.1111/j.1432-2277.2009.00915.x]
7 Lee SG,Moon DB.Living donor liver transplantation for hepatocellular carcinoma.Recent Results Cancer Res 2013;190:165 -179[PMID:22941020 DOI:10.1007/978-3-642-16037-0_11]
8 Moon DB,Lee SG,Hwang S,Kim KH,Ahn CS,Ha TY,Song GW,Jung DH,Park GC,Namkoong JM,Park HW,Park YH,Park CS.More than 300 consecutive living donor liver transplants a year at a single center.Transplant Proc 2013;45:1942-1947[PMID:23769079 DOI:10.1016/j.transproceed.2013.02.041]
9 Song GW,Lee SG,Hwang S,Ahn CS,Moon DB,Kim KH,Ha TY,Jung DH,Park GC,Namgung JM,Park CS,Park HW,Park YH.Successful experiences of ABO-incompatible adult living donor liver transplantation in a single institute:no immunological failure in 10 consecutive cases.Transplant Proc2013;45:272-275[PMID:23375314 DOI:10.1016/j.transprocee d.2012.06.079]
10 Starzl TE.The long reach of liver transplantation.Nat Med2012;18:1489-1492[PMID:23042359 DOI:10.1038/nm.2927]
11 Starzl TE,Marchioro TL,Vonkaulla KN,Hermann G,Brittain RS,Waddell WR.Homotransplantation of the liver in humans.Surg Gynecol Obstet 1963;117:659-676[PMID:14100514]
12 Starzl TE,Groth CG,Brettschneider L,Penn I,Fulginiti VA,Moon JB,Blanchard H,Martin AJ,Porter KA.Orthotopic homotransplantation of the human liver.Ann Surg 1968;168:392 -415[PMID:4877589 DOI:10.1097/00007890-196709000-00033]
13 Shapiro HA.Brain death and organ transplantation.J Forensic Med 1968;15:89-90[PMID:5729525]
14 Starzl TE,Iwatsuki S,Klintmalm G,Schrter GP,Weil R,Koep LJ,Porter KA.Liver transplantation,1980,with particular reference to cyclosporin-A.Transplant Proc 1981;13:281 -285[PMID:7022839]
15 Starzl TE,Klintmalm GB,Porter KA,Iwatsuki S,Schrter GP.Liver transplantation with use of cyclosporin a and prednisone.N Engl J Med 1981;305:266-269[PMID:7017414DOI:10.1056/NEJM198107303050507]
16 National Institutes of Health Consensus Development Conference Statement:liver transplantation--June 20-23,1983.Hepatology 1984;4:107S-110S[PMID:6363254]
17 National Organ Transplant Act:Public Law 98-507.US Statut Large 1984;98:2339-2348[PMID:11660818]
18 Pichlmayr R,Ringe B,Gubernatis G,Hauss J,Bunzendahl H.[Transplantation of a donor liver to 2 recipients(splitting transplantation)--a new method in the further development of segmental liver transplantation].Langenbecks Arch Chir1988;373:127-130[PMID:3287073]
19 Broelsch CE,Emond JC,Whitington PF,Thistlethwaite JR,Baker AL,Lichtor JL.Application of reduced-size liver transplants as split grafts,auxiliary orthotopic grafts,and living related segmental transplants.Ann Surg 1990;212:368-375;discussion 375-377[PMID:2396888]
20 Bhangui P,Vibert E,Majno P,Salloum C,Andreani P,Zocrato J,Ichai P,Saliba F,Adam R,Castaing D,Azoulay D.Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma:living versus deceased donor transplantation.Hepatology 2011;53:1570-1579[PMID:21520172 DOI:10 .1002/hep.24231]
21 Gondolesi GE,Roayaie S,Muoz L,Kim-Schluger L,Schiano T,Fishbein TM,Emre S,Miller CM,Schwartz ME.Adult living donor liver transplantation for patients with hepatocellular carcinoma:extending UNOS priority criteria.Ann Surg 2004;239:142-149[PMID:14745320 DOI:10.1097/01.sla.0000109022.32391.eb]
22 Grant RC,Sandhu L,Dixon PR,Greig PD,Grant DR,McGilvray ID.Living vs.deceased donor liver transplantation for hepatocellular carcinoma:a systematic review and meta-analysis.Clin Transplant 2013;27:140-147[PMID:23157398DOI:10.1111/ctr.12031]
23 Kaihara S,Kiuchi T,Ueda M,Oike F,Fujimoto Y,Ogawa K,Kozaki K,Tanaka K.Living-donor liver transplantation for hepatocellular carcinoma.Transplantation 2003;75:S37-S40[PMID:12589138 DOI:10.1097/01.TP.0000047029.02806.16]
24 Sandhu L,Sandroussi C,Guba M,Selzner M,Ghanekar A,Cattral MS,McGilvray ID,Levy G,Greig PD,Renner EL,Grant DR.Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma:comparable survival and recurrence.Liver Transpl 2012;18:315 -322[PMID:22140013 DOI:10.1002/lt.22477]
25 Todo S,Furukawa H,Japanese Study Group on Organ Transplantation.Living donor liver transplantation for adult patients with hepatocellular carcinoma:experience in Japan.Ann Surg 2004;240:451-459;discussion 459-461[PMID:15319716 DOI:10.1097/01.sla.0000137129.98894.42]
26 Saidi RF,Jabbour N,Li Y,Shah SA,Bozorgzadeh A.Is left lobe adult-to-adult living donor liver transplantation ready for widespread useThe US experience(1998-2010).HPB(Oxford)2012;14:455-460[PMID:22672547 DOI:10.1111/j.1477-2574.2012.00475.x]
27 Saidi RF,Markmann JF,Jabbour N,Li Y,Shah SA,Cosimi AB,Bozorgzadeh A.The faltering solid organ donor pool in the United States(2001-2010).World J Surg 2012;36:2909-2913[PMID:22933050 DOI:10.1007/s00268-012-1748-0]
28 Muzaale AD,Dagher NN,Montgomery RA,Taranto SE,McBride MA,Segev DL.Estimates of early death,acute liver failure,and long-term mortality among live liver donors.Gastroenterology 2012;142:273-280[PMID:22108193 DOI:10 .1053/j.gastro.2011.11.015]
29 Roll GR,Roberts JP.Left versus right lobe liver donation.Am J Transplant 2014;14:251-252[PMID:24304562 DOI:10 .1111/ajt.12556]
30 Roll GR,Parekh JR,Parker WF,Siegler M,Pomfret EA,Ascher NL,Roberts JP.Left hepatectomy versus right hepatectomy for living donor liver transplantation:shifting the risk from the donor to the recipient.Liver Transpl 2013;19:472 -481[PMID:23447523 DOI:10.1002/lt.23608]
31 Ghobrial RM,Freise CE,Trotter JF,Tong L,Ojo AO,Fair JH,Fisher RA,Emond JC,Koffron AJ,Pruett TL,Olthoff KM.Donor morbidity after living donation for liver transplantation.Gastroenterology 2008;135:468-476[PMID:18505689DOI:10.1053/j.gastro.2008.04.018]
32 Geissler EK,Schlitt HJ.Immunosuppression for liver transplantation.Gut 2009;58:452-463[PMID:19052024 DOI:10 .1136/gut.2008.163527]
33 Sgourakis G,Radtke A,Fouzas I,Mylona S,Goumas K,Gockel I,Lang H,Karaliotas C.Corticosteroid-free immunosuppression in liver transplantation:a meta-analysis and meta-regression of outcomes.Transpl Int 2009;22:892-905[PMID:19453997 DOI:10 .1111/j.1432-2277.2009.00893.x]
34 Schlitt HJ,Jonas S,Ganten TM,Grannas G,Moench C,Rauchfuss F,Obed A,Tisone G,Pinna AD,Gerunda GE,Beckebaum S.Effects of mycophenolate mofetil introduction in liver transplant patients:results from an observational,non-interventional,multicenter study(LOBSTER).Clin Transplant 2013;27:368 -378[PMID:23405863 DOI:10.1111/ctr.12097]
35 Vivarelli M,Cucchetti A,Piscaglia F,La Barba G,Bolondi L,Cavallari A,Pinna AD.Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma:key role of immunosuppression.Liver Transpl 2005;11 :497-503[PMID:15838913 DOI:10.1002/lt.20391]
36 Farkas SA,Schnitzbauer AA,Kirchner G,Obed A,Banas B,Schlitt HJ.Calcineurin inhibitor minimization protocols in liver transplantation.Transpl Int 2009;22:49-60[PMID:19121146 DOI:10.1111/j.1432-2277.2008.00796.x]
37 Schnitzbauer AA,Zuelke C,Graeb C,Rochon J,Bilbao I,Burra P,de Jong KP,Duvoux C,Kneteman NM,Adam R,Bechstein WO,Becker T,Beckebaum S,Chazouillères O,CilloU,Colledan M,Fndrich F,Gugenheim J,Hauss JP,Heise M,Hidalgo E,Jamieson N,Knigsrainer A,Lamby PE,Lerut JP,Mkisalo H,Margreiter R,Mazzaferro V,Mutzbauer I,Otto G,Pageaux GP,Pinna AD,Pirenne J,Rizell M,Rossi G,Rostaing L,Roy A,Turrion VS,Schmidt J,Troisi RI,van Hoek B,Valente U,Wolf P,Wolters H,Mirza DF,Scholz T,Steininger R,Soderdahl G,Strasser SI,Jauch KW,Neuhaus P,Schlitt HJ,Geissler EK.A prospective randomised,open-labeled,trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.BMC Cancer 2010;10:190[PMID:20459775 DOI:10.1186/1471-2407-10-190]
38 Guba M,von Breitenbuch P,Steinbauer M,Koehl G,Flegel S,Hornung M,Bruns CJ,Zuelke C,Farkas S,Anthuber M,Jauch KW,Geissler EK.Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor.Nat Med 2002;8:128 -135[PMID:11821896 DOI:10.1038/nm0202-128]
39 Shirouzu Y,Ryschich E,Salnikova O,Kerkadze V,Schmidt J,Engelmann G.Rapamycin inhibits proliferation and migration of hepatoma cells in vitro.J Surg Res 2010;159:705-713[PMID:19482307 DOI:10.1016/j.jss.2008.07.035]
40 Salvadori M.Antineoplastic effects of mammalian target of rapamycine inhibitors.World J Transplant 2012;2:74-83[PMID:24175199 DOI:10.5500/wjt.v2.i5.74]
41 Dahlke MH,Hoogduijn M,Eggenhofer E,Popp FC,Renner P,Slowik P,Rosenauer A,Piso P,Geissler EK,Lange C,Chabannes D,Mazzanti B,Bigenzahn S,Bertolino P,Kunter U,Introna M,Rambaldi A,Capelli C,Perico N,Casiraghi F,Noris M,Gotti E,Seifert M,Saccardi R,Verspaget HW,van Hoek B,Bartholomew A,Wekerle T,Volk HD,Remuzzi G,Deans R,Lazarus H,Schlitt HJ,Baan CC.Toward MSC in solid organ transplantation:2008 position paper of the MISOT study group.Transplantation 2009;88:614-619[PMID:19741455 DOI:10.1097/TP.0b013e3181b4425a]
42 Dillmann J,Popp FC,Fillenberg B,Zeman F,Eggenhofer E,Farkas S,Scherer MN,Koller M,Geissler EK,Deans R,Ladenheim D,Loss M,Schlitt HJ,Dahlke MH.Treatment-emergent adverse events after infusion of adherent stem cells:the MiSOT-I score for solid organ transplantation.Trials 2012;13 :211[PMID:23151227 DOI:10.1186/1745-6215-13-211]
43 Popp FC,Renner P,Eggenhofer E,Slowik P,Geissler EK,Piso P,Schlitt HJ,Dahlke MH.Mesenchymal stem cells as immunomodulators after liver transplantation.Liver Transpl2009;15:1192-1198[PMID:19790154 DOI:10.1002/lt.21862]
44 Parkin DM,Bray F,Ferlay J,Pisani P.Global cancer statistics,2002.CA Cancer J Clin 2005;55:74-108[PMID:15761078DOI:10.3322/canjclin.55.2.74]
45 Anthony PP.Hepatocellular carcinoma:an overview.Histopathology 2001;39:109-118[PMID:11493326 DOI:10.1046/j.1365-2559.2001.01188.x]
46 Block TM,Mehta AS,Fimmel CJ,Jordan R.Molecular viral oncology of hepatocellular carcinoma.Oncogene 2003;22:5093-5107[PMID:12910247 DOI:10.1038/sj.onc.1206557]
47 Gomaa AI,Khan SA,Toledano MB,Waked I,Taylor-Robinson SD.Hepatocellular carcinoma:epidemiology,risk factors and pathogenesis.World J Gastroenterol 2008;14:4300-4308[PMID:18666317 DOI:10.3748/wjg.14.4300]
48 Montalto G,Cervello M,Giannitrapani L,Dantona F,Terranova A,Castagnetta LA.Epidemiology,risk factors,and natural history of hepatocellular carcinoma.Ann N Y Acad Sci 2002;963 :13-20[PMID:12095924 DOI:10.1111/j.1749-6632.2002.tb04090.x]
49 Ringe B,Pichlmayr R,Wittekind C,Tusch G.Surgical treatment of hepatocellular carcinoma:experience with liver resection and transplantation in 198 patients.World J Surg1991;15:270-285[PMID:1851588 DOI:10.1007/BF01659064]
50 Iwatsuki S,Starzl TE,Sheahan DG,Yokoyama I,Demetris AJ,Todo S,Tzakis AG,Van Thiel DH,Carr B,Selby R.Hepatic resection versus transplantation for hepatocellularcarcinoma.Ann Surg 1991;214:221-228;discussion 228-229[PMID:1656903 DOI:10.1097/00000658-199109000-00005]
51 Yao FY,Ferrell L,Bass NM,Watson JJ,Bacchetti P,Venook A,Ascher NL,Roberts JP.Liver transplantation for hepatocellular carcinoma:expansion of the tumor size limits does not adversely impact survival.Hepatology 2001;33:1394-1403[PMID:11391528 DOI:10.1053/jhep.2001.24563]
52 Mazzaferro V,Regalia E,Doci R,Andreola S,Pulvirenti A,Bozzetti F,Montalto F,Ammatuna M,Morabito A,Gennari L.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med 1996;334:693 -699[PMID:8594428 DOI:10.1056/NEJM199603143341104]
53 Mazzaferro V,Bhoori S,Sposito C,Bongini M,Langer M,Miceli R,Mariani L.Milan criteria in liver transplantation for hepatocellular carcinoma:an evidence-based analysis of 15years of experience.Liver Transpl 2011;17 Suppl 2:S44-S57[PMID:21695773 DOI:10.1002/lt.22365]
54 Dhir M,Lyden ER,Smith LM,Are C.Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma:a meta-analysis.HPB(Oxford)2012;14:635 -645[PMID:22882201 DOI:10.1111/j.1477-2574.2012.00500.x]
55 Earl TM,Chapman WC.Transplantation for hepatocellular carcinoma:the North American experience.Recent Results Cancer Res 2013;190:145-164[PMID:22941019 DOI:10.1007/978 -3-642-16037-0_10]
56 Yao FY.Liver transplantation for hepatocellular carcinoma:beyond the Milan criteria.Am J Transplant 2008;8:1982-1989[PMID:18727702 DOI:10.1111/j.1600-6143.2008.02351.x]
57 Belghiti J,Cortes A,Abdalla EK,Régimbeau JM,Prakash K,Durand F,Sommacale D,Dondero F,Lesurtel M,Sauvanet A,Farges O,Kianmanesh R.Resection prior to liver transplantation for hepatocellular carcinoma.Ann Surg 2003;238:885 -892;discussion 892-893[PMID:14631225 DOI:10.1097/01.sla.0000098621.74851.65]
58 Castroagudín JF,Delgado M,Villanueva A,Bustamante M,Martínez J,Otero E,ToméS,Martínez SM,Segade FR,Conde R,Dominguez-Muoz E,Varo E.Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates.Transplant Proc 2005;37:3871-3873[PMID:16386568 DOI:10 .1016/j.transproceed.2005.09.168]
59 Chua TC,Saxena A,Chu F,Morris DL.Hepatic resection for transplantable hepatocellular carcinoma for patients within Milan and UCSF criteria.Am J Clin Oncol 2012;35:141-145[PMID:21336092 DOI:10.1097/COC.0b013e318209ab7d]
60 Facciuto ME,Singh MK,Rochon C,Sharma J,Gimenez C,Katta U,Moorthy CR,Bentley-Hibbert S,Rodriguez-Davalos M,Wolf DC.Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis:evaluation of radiological and pathological response.J Surg Oncol 2012;105:692-698[PMID:21960321 DOI:10.1002/jso.22104]
61 Lu DS,Yu NC,Raman SS,Lassman C,Tong MJ,Britten C,Durazo F,Saab S,Han S,Finn R,Hiatt JR,Busuttil RW.Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.Hepatology 2005;41 :1130-1137[PMID:15841454 DOI:10.1002/hep.20688]
62 O'Connor JK,Trotter J,Davis GL,Dempster J,Klintmalm GB,Goldstein RM.Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation.Liver Transpl 2012;18:949-954[PMID:22467602 DOI:10.1002/lt.23439]
63 Pompili M,Mirante VG,Rondinara G,Fassati LR,Piscaglia F,Agnes S,Covino M,Ravaioli M,Fagiuoli S,Gasbarrini G,Rapaccini GL.Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation:Assessment of efficacy at explant analysis and of safety for tumor recurrence.Liver Transpl 2005;11:1117-1126[PMID:16123960 DOI:10.1002/lt.20469]
64 Poon RT,Fan ST,Lo CM,Liu CL,Wong J.Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function:implications for a strategy of salvage transplantation.Ann Surg 2002;235:373-382[PMID:11882759 DOI:10 .1097/00000658-200203000-00009]
65 Majno P,Lencioni R,Mornex F,Girard N,Poon RT,Cherqui D.Is the treatment of hepatocellular carcinoma on the waiting list necessaryLiver Transpl 2011;17 Suppl 2:S98-108[PMID:21954097 DOI:10.1002/lt.22391]
66 Yao FY,Bass NM,Nikolai B,Merriman R,Davern TJ,Kerlan R,Ascher NL,Roberts JP.A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma:implications for the current organ allocation policy.Liver Transpl 2003;9:684 -692[PMID:12827553 DOI:10.1053/jlts.2003.50147]
67 European Association For The Study Of The Liver,European Organisation For Research And Treatment Of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma.J Hepatol 2012;56:908-943[PMID:22424438 DOI:10.1016/j.jhep.2011.12.001]
68 Bharat A,Brown DB,Crippin JS,Gould JE,Lowell JA,Shenoy S,Desai NM,Chapman WC.Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival.J Am Coll Surg 2006;203:411-420[PMID:17000383 DOI:10.1016/j.jamcollsurg.2006.06.016]
69 Chan KM,Yu MC,Chou HS,Wu TJ,Lee CF,Lee WC.Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation.Ann Surg Oncol 2011;18:2638-2646[PMID:21584831 DOI:10.1245/s10434-011-1779-z]
70 Graziadei IW,Sandmueller H,Waldenberger P,Koenigsrainer A,Nachbaur K,Jaschke W,Margreiter R,Vogel W.Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.Liver Transpl 2003;9:557 -563[PMID:12783395 DOI:10.1053/jlts.2003.50106]
71 Clavien PA,Lesurtel M,Bossuyt PM,Gores GJ,Langer B,Perrier A.Recommendations for liver transplantation for hepatocellular carcinoma:an international consensus conference report.Lancet Oncol 2012;13:e11-e22[PMID:22047762DOI:10.1016/S1470-2045(11)70175-9]
72 Mazzaferro V,Llovet JM,Miceli R,Bhoori S,Schiavo M,Mariani L,Camerini T,Roayaie S,Schwartz ME,Grazi GL,Adam R,Neuhaus P,Salizzoni M,Bruix J,Forner A,De Carlis L,Cillo U,Burroughs AK,Troisi R,Rossi M,Gerunda GE,Lerut J,Belghiti J,Boin I,Gugenheim J,Rochling F,Van Hoek B,Majno P.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria:a retrospective,exploratory analysis.Lancet Oncol 2009;10:35 -43[PMID:19058754 DOI:10.1016/S1470-2045(08)70284-5]
73 Menon KV,Hakeem AR,Heaton ND.Meta-analysis:recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.Aliment Pharmacol Ther2013;37:411-419[PMID:23278125 DOI:10.1111/apt.12185]
74 El-Serag HB,Davila JA.Is fibrolamellar carcinoma different from hepatocellular carcinomaA US population-based study.Hepatology 2004;39:798-803[PMID:14999699 DOI:10 .1002/hep.20096]
75 Kakar S,Burgart LJ,Batts KP,Garcia J,Jain D,Ferrell LD.Clinicopathologic features and survival in fibrolamellar carcinoma:comparison with conventional hepatocellular carcinoma with and without cirrhosis.Mod Pathol 2005;18:1417-1423[PMID:15920538 DOI:10.1038/modpathol.3800449]
76 Pinna AD,Iwatsuki S,Lee RG,Todo S,Madariaga JR,Marsh JW,Casavilla A,Dvorchik I,Fung JJ,Starzl TE.Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.Hepatology 1997;26:877-883[PMID:9328308 DOI:10 .1002/hep.510260412]
77 Stipa F,Yoon SS,Liau KH,Fong Y,Jarnagin WR,D’Angelica M,Abou-Alfa G,Blumgart LH,DeMatteo RP.Outcome of pa-tients with fibrolamellar hepatocellular carcinoma.Cancer 2006;106 :1331-1338[PMID:16475212 DOI:10.1002/cncr.21703]
78 El-Gazzaz G,Wong W,El-Hadary MK,Gunson BK,Mirza DF,Mayer AD,Buckels JA,McMaster P.Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma.Transpl Int 2000;13 Suppl 1:S406-S409[PMID:11112043 DOI:10.1007/s001470050372]
79 Bragazzi MC,Carpino G,Venere R,Semeraro R,Gentile R,Gaudio E,Alvaro,D.Cholangiocarcinoma:Epidemiology and risk factors.Transl.Gastrointest.Cancer 2012;1:21-32[DOI:10.3978/j.issn.2224-4778.2011.11.04]
80 Burke EC,Jarnagin WR,Hochwald SN,Pisters PW,Fong Y,Blumgart LH.Hilar Cholangiocarcinoma:patterns of spread,the importance of hepatic resection for curative operation,and a presurgical clinical staging system.Ann Surg 1998;228:385-394[PMID:9742921 DOI:10.1097/00000658-199809000-00011]
81 Choi SB,Kim KS,Choi JY,Park SW,Choi JS,Lee WJ,Chung JB.The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection:association of lymph node metastasis and lymph node dissection with survival.Ann Surg Oncol 2009;16:3048-3056[PMID:19626372DOI:10.1245/s10434-009-0631-1]
82 DeOliveira ML,Cunningham SC,Cameron JL,Kamangar F,Winter JM,Lillemoe KD,Choti MA,Yeo CJ,Schulick RD.Cholangiocarcinoma:thirty-one-year experience with 564patients at a single institution.Ann Surg 2007;245:755-762[PMID:17457168 DOI:10.1097/01.sla.0000251366.62632.d3]
83 Hemming AW,Reed AI,Fujita S,Foley DP,Howard RJ.Surgical management of hilar cholangiocarcinoma.Ann Surg2005;241:693-699;discussion 699-702[PMID:15849505 DOI:10 .1097/01.sla.0000160701.38945.82]
84 Wang Y,Li J,Xia Y,Gong R,Wang K,Yan Z,Wan X,Liu G,Wu D,Shi L,Lau W,Wu M,Shen F.Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy.J Clin Oncol 2013;31:1188-1195[PMID:23358969 DOI:10 .1200/JCO.2012.41.5984]
85 Pichlmayr R,Weimann A,Oldhafer KJ,Schlitt HJ,Klempnauer J,Bornscheuer A,Chavan A,Schmoll E,Lang H,Tusch G.Role of liver transplantation in the treatment of unresectable liver cancer.World J Surg 1995;19:807-813[PMID:8553670 DOI:10.1007/BF00299775]
86 Weimann A,Varnholt H,Schlitt HJ,Lang H,Flemming P,Hustedt C,Tusch G,Raab R.Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma.Br J Surg 2000;87:1182-1187[PMID:10971425 DOI:10.1046/j.1365-2168.2000.01532.x]
87 Rea DJ,Heimbach JK,Rosen CB,Haddock MG,Alberts SR,Kremers WK,Gores GJ,Nagorney DM.Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma.Ann Surg 2005;242 :451-458;discussion 458-461[PMID:16135931 DOI:10 .1097/01.sla.0000179678.13285.fa]
88 Rosen CB,Heimbach JK,Gores GJ.Surgery for cholangiocarcinoma:the role of liver transplantation.HPB(Oxford)2008;10:186-189[PMID:18773052 DOI:10.1080/13651820801992542]
89 Gu J,Bai J,Shi X,Zhou J,Qiu Y,Wu Y,Jiang C,Sun X,Xu F,Zhang Y,Ding Y.Efficacy and safety of liver transplantation in patients with cholangiocarcinoma:a systematic review and meta-analysis.Int J Cancer 2012;130:2155-2163[PMID:21387295 DOI:10.1002/ijc.26019]
90 Organ Procurement and Transplantation Network.Allocation of livers.Accessed 26 July 2013.Available from:URL:http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf
91 Pandey D,Lee KH,Tan KC.The role of liver transplantation for hilar cholangiocarcinoma.Hepatobiliary Pancreat Dis Int2007;6:248-253[PMID:17548246]
92 Alvaro D,Cannizzaro R,Labianca R,Valvo F,Farinati F,Italian Society of Gastroenterology(SIGE),Italian Associationof Hospital Gastroenterology(AIGO),Italian Association of Medical Oncology(AIOM),Italian Association of Oncological Radiotherapy(AIRO).Cholangiocarcinoma:A position paper by the Italian Society of Gastroenterology(SIGE),the Italian Association of Hospital Gastroenterology(AIGO),the Italian Association of Medical Oncology(AIOM)and the Italian Association of Oncological Radiotherapy(AIRO).Dig Liver Dis 2010;42:831-838[PMID:20702152 DOI:10.1016/j.dld.2010.06.005]
93 Axelrod D,Koffron A,Kulik L,Al-Saden P,Mulcahy M,Baker T,Fryer J,Abecassis M.Living donor liver transplant for malignancy.Transplantation 2005;79:363-366[PMID:15699771 DOI:10.1097/01.TP.0000151658.25247.C4]
94 Jonas S,Mittler J,Pascher A,Theruvath T,Thelen A,Klupp J,Langrehr JM,Neuhaus P.Extended indications in livingdonor liver transplantation:bile duct cancer.Transplantation 2005;80:S101-S104[PMID:16286884 DOI:10.1097/01.tp.0000187106.29908.2b]
95 Schüle S,Altendorf-Hofmann A,UteF,RauchfuF,Freesmeyer M,Knsel T,Dittmar Y,Settmacher U.Liver transplantation for hilar cholangiocarcinoma--a single-centre experience.Langenbecks Arch Surg 2013;398:71-77[PMID:23053456 DOI:10.1007/s00423-012-1007-8]
96 Weiss SW,Enzinger FM.Epithelioid hemangioendothelioma:a vascular tumor often mistaken for a carcinoma.Cancer1982;50:970-981[PMID:7093931 DOI:10.1002/1097-0142(19820901)50]
97 Ishak KG,Sesterhenn IA,Goodman ZD,Rabin L,Stromeyer FW.Epithelioid hemangioendothelioma of the liver:a clinicopathologic and follow-up study of 32 cases.Hum Pathol 1984;15:839-852[PMID:6088383 DOI:10.1016/S0046-8177(84)80145-8]
98 Marino IR,Todo S,Tzakis AG,Klintmalm G,Kelleher M,Iwatsuki S,Starzl TE,Esquivel CO.Treatment of hepatic epithelioid hemangioendothelioma with liver transplantation.Cancer 1988;62:2079-2084[PMID:3052779]
99 Hertl M,Cosimi AB.Liver transplantation for malignancy.Oncologist 2005;10:269-281[PMID:15821247 DOI:10.1634/theoncologist.10-4-269]
100 Rodriguez JA,Becker NS,O’Mahony CA,Goss JA,Aloia TA.Long-term outcomes following liver transplantation for hepatic hemangioendothelioma:the UNOS experience from1987 to 2005.J Gastrointest Surg 2008;12:110-116[PMID:17710508 DOI:10.1007/s11605-007-0247-3]
101 Makhlouf HR,Ishak KG,Goodman ZD.Epithelioid hemangioendothelioma of the liver:a clinicopathologic study of 137 cases.Cancer 1999;85:562-582[PMID:10091730 DOI:10 .1002/(SICI)1097-0142(19990201)85]
102 Mehrabi A,Kashfi A,Fonouni H,Schemmer P,Schmied BM,Hallscheidt P,Schirmacher P,Weitz J,Friess H,Buchler MW,Schmidt J.Primary malignant hepatic epithelioid hemangioendothelioma:a comprehensive review of the literature with emphasis on the surgical therapy.Cancer 2006;107:2108-2121[PMID:17019735 DOI:10.1002/cncr.22225]
103 Wang LR,Zhou JM,Zhao YM,He HW,Chai ZT,Wang M,Ji Y,Chen Y,Liu C,Sun HC,Wu WZ,Ye QH,Zhou J,Fan J,Tang ZY,Wang L.Clinical experience with primary hepatic epithelioid hemangioendothelioma:retrospective study of 33patients.World J Surg 2012;36:2677-2683[PMID:22890877DOI:10.1007/s00268-012-1714-x]
104 Lerut JP,Orlando G,Adam R,Schiavo M,Klempnauer J,Mirza D,Boleslawski E,Burroughs A,Sellés CF,Jaeck D,Pfitzmann R,Salizzoni M,Sderdahl G,Steininger R,Wettergren A,Mazzaferro V,Le Treut YP,Karam V.The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma:report of the European liver transplant registry.Ann Surg 2007;246:949-957;discussion 957[PMID:18043096 DOI:10.1097/SLA.0b013e31815c2a70]
105 Ben-Haim M,Roayaie S,Ye MQ,Thung SN,Emre S,Fishbein TA,Sheiner PM,Miller CM,Schwartz ME.Hepaticepithelioid hemangioendothelioma:resection or transplantation,which and whenLiver Transpl Surg 1999;5:526-531[PMID:10545542 DOI:10.1002/lt.500050612]
106 Grotz TE,Nagorney D,Donohue J,Que F,Kendrick M,Farnell M,Harmsen S,Mulligan D,Nguyen J,Rosen C,Reid-Lombardo KM.Hepatic epithelioid haemangioendothelioma:is transplantation the only treatment optionHPB(Oxford)2010;12:546 -553[PMID:20887322 DOI:10.1111/j.1477-2574.2010.00213.x]
107 Nudo CG,Yoshida EM,Bain VG,Marleau D,Wong P,Marotta PJ,Renner E,Watt KD,Deschênes M.Liver transplantation for hepatic epithelioid hemangioendothelioma:the Canadian multicentre experience.Can J Gastroenterol 2008;22 :821-824[PMID:18925305]
108 Madariaga JR,Marino IR,Karavias DD,Nalesnik MA,Doyle HR,Iwatsuki S,Fung JJ,Starzl TE.Long-term results after liver transplantation for primary hepatic epithelioid hemangioendothelioma.Ann Surg Oncol 1995;2:483-487[PMID:8591077 DOI:10.1007/BF02307080]
109 Yokoyama I,Todo S,Iwatsuki S,Starzl TE.Liver transplantation in the treatment of primary liver cancer.Hepatogastroenterology 1990;37:188-193[PMID:2160421]
110 Debre R,Mozziconacci P,Habib E,Habib R.[Hepatoblastoma:malignant tumor of the liver with embryonic cells].Arch Fr Pediatr 1954;11:1013-1034[PMID:13229384]
111 Grossman EJ,Millis JM.Liver transplantation for non-hepatocellular carcinoma malignancy:Indications,limitations,and analysis of the current literature.Liver Transpl 2010;16:930 -942[PMID:20677284 DOI:10.1002/lt.22106]
112 Meyers RL,Tiao GM,Dunn SP,Langham MR.Liver transplantation in the management of unresectable hepatoblastoma in children.Front Biosci(Elite Ed)2012;4:1293-1302[PMID:22201955 DOI:10.2741/E460]
113 Weksberg R,Shuman C,Smith AC.Beckwith-Wiedemann syndrome.Am J Med Genet C Semin Med Genet 2005;137C:12 -23[PMID:16010676 DOI:10.1002/ajmg.c.30058]
114 Siciliano M,De Candia E,Ballarin S,Vecchio FM,Servidei S,Annese R,Landolfi R,Rossi L.Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease.J Clin Gastroenterol 2000;31:80-82[PMID:10914784DOI:10.1097/00004836-200007000-00020]
115 McLaughlin CC,Baptiste MS,Schymura MJ,Nasca PC,Zdeb MS.Maternal and infant birth characteristics and hepatoblastoma.Am J Epidemiol 2006;163:818-828[PMID:16510543DOI:10.1093/aje/kwj104]
116 Maruyama K,Ikeda H,Koizumi T.Hepatoblastoma associated with trisomy 18 syndrome:a case report and a review of the literature.Pediatr Int 2001;43:302-305[PMID:11380930DOI:10.1046/j.1442-200x.2001.01380.x]
117 Giardiello FM,Petersen GM,Brensinger JD,Luce MC,Cayouette MC,Bacon J,Booker SV,Hamilton SR.Hepatoblastoma and APC gene mutation in familial adenomatous polyposis.Gut 1996;39:867-869[PMID:9038672]
118 Zimmermann A.The emerging family of hepatoblastoma tumours:from ontogenesis to oncogenesis.Eur J Cancer 2005;41:1503-1514[PMID:15982867 DOI:10.1016/j.ejca.2005.02.035]
119 Brown J,Perilongo G,Shafford E,Keeling J,Pritchard J,Brock P,Dicks-Mireaux C,Phillips A,Vos A,Plaschkes J.Pretreatment prognostic factors for children with hepatoblastoma--results from the International Society of Paediatric Oncology(SIOP)study SIOPEL 1.Eur J Cancer 2000;36:1418-1425[PMID:10899656 DOI:10.1016/S0959-8049(00)00074-5]
120 Zsíros J,Maibach R,Shafford E,Brugieres L,Brock P,Czauderna P,Roebuck D,Childs M,Zimmermann A,Laithier V,Otte JB,de Camargo B,MacKinlay G,Scopinaro M,Aronson D,Plaschkes J,Perilongo G.Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery:final results of the SIOPEL-3 HR study.J Clin Oncol 2010;28:2584-2590[PMID:20406943DOI:10.1200/JCO.2009.22.4857]
121 Browne M,Sher D,Grant D,Deluca E,Alonso E,Whitington PF,Superina RA.Survival after liver transplantation for hepatoblastoma:a 2-center experience.J Pediatr Surg 2008;43:1973-1981[PMID:18970927 DOI:10.1016/j.jpedsurg.2008.05.031]
122 Faraj W,Dar F,Marangoni G,Bartlett A,Melendez HV,Hadzic D,Dhawan A,Mieli-Vergani G,Rela M,Heaton N.Liver transplantation for hepatoblastoma.Liver Transpl 2008;14 :1614-1619[PMID:18975296 DOI:10.1002/lt.21586]
123 Beaunoyer M,Vanatta JM,Ogihara M,Strichartz D,Dahl G,Berquist WE,Castillo RO,Cox KL,Esquivel CO.Outcomes of transplantation in children with primary hepatic malignancy.Pediatr Transplant 2007;11:655-660[PMID:17663690DOI:10.1111/j.1399-3046.2007.00751.x]
124 Avila LF,Luis AL,Hernandez F,Garcia Miguel P,Jara P,Andres AM,Lopez Santamaría M,Tovar JA.Liver transplantation for malignant tumours in children.Eur J Pediatr Surg 2006;16:411 -414[PMID:17211789 DOI:10.1055/s-2006-924730]
125 Austin MT,Leys CM,Feurer ID,Lovvorn HN,O’Neill JA,Pinson CW,Pietsch JB.Liver transplantation for childhood hepatic malignancy:a review of the United Network for Organ Sharing(UNOS)database.J Pediatr Surg 2006;41:182-186[PMID:16410130 DOI:10.1016/j.jpedsurg.2005.10.091]
126 Mejia A,Langnas AN,Shaw BW,Torres C,Sudan DL.Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center.Clin Transplant 2005;19:721-725[PMID:16313316 DOI:10.1111/j.1399-0012.2005.00410.x]
127 Kasahara M,Ueda M,Haga H,Hiramatsu H,Kobayashi M,Adachi S,Sakamoto S,Oike F,Egawa H,Takada Y,Tanaka K.Living-donor liver transplantation for hepatoblastoma.Am J Transplant 2005;5:2229-2235[PMID:16095502 DOI:10.1111/j.1600-6143.2005.01003.x]
128 Otte JB,Pritchard J,Aronson DC,Brown J,Czauderna P,Maibach R,Perilongo G,Shafford E,Plaschkes J,International Society of Pediatric Oncology(SIOP).Liver transplantation for hepatoblastoma:results from the International Society of Pediatric Oncology(SIOP)study SIOPEL-1 and review of the world experience.Pediatr Blood Cancer 2004;42:74 -83[PMID:14752798 DOI:10.1002/pbc.10376]
129 Molmenti EP,Wilkinson K,Molmenti H,Roden JS,Squires RH,Fasola CG,Tomlinson G,Nagata DE,D’Amico L,Lopez MJ,Savino LM,Marubashi S,Sanchez EQ,Goldstein RM,Levy MF,Andrews W,Andersen JA,Klintmalm GB.Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population.Am J Transplant 2002;2:535-538[PMID:12118897 DOI:10.1034/j.1600-6143.2002.20607.x]
130 Chardot C,Saint Martin C,Gilles A,Brichard B,Janssen M,Sokal E,Clapuyt P,Lerut J,Reding R,Otte JB.Living-related liver transplantation and vena cava reconstruction after total hepatectomy including the vena cava for hepatoblastoma.Transplantation 2002;73:90-92[PMID:11792985 DOI:10.1097/00007890-200201150-00017]
131 Reyes JD,Carr B,Dvorchik I,Kocoshis S,Jaffe R,Gerber D,Mazariegos GV,Bueno J,Selby R.Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence.J Pediatr 2000;136:795-804[PMID:10839879 DOI:10.1016/S0022-3476(00)44469-0]
132 Tsoucalas G,Karamanou M,Androutsos G.The eminent German pathologist Siegfried Oberndorfer(1876-1944)and his landmark work on carcinoid tumors.Ann of Gastroenterol2011;24:98-100[PMID:24713679]
133 Toledo SP,Loureno DM,Toledo RA.A differential diagnosis of inherited endocrine tumors and their tumor counterparts.Clinics(Sao Paulo)2013;68:1039-1056[PMID:23917672 DOI:10.6061/clinics/2013(07)24]
134 Oberg K,Castellano D.Current knowledge on diagnosis and staging of neuroendocrine tumors.Cancer Metastasis Rev 2011;30 Suppl 1:3-7[PMID:21311954 DOI:10.1007/s10555-011-9292-1]
135 Ramage JK,Davies AH,Ardill J,Bax N,Caplin M,Grossman A,Hawkins R,McNicol AM,Reed N,Sutton R,Thakker R,Aylwin S,Breen D,Britton K,Buchanan K,Corrie P,Gillams A,Lewington V,McCance D,Meeran K,Watkinson A.Guidelines for the management of gastroenteropancreatic neuroendocrine(including carcinoid)tumours.Gut 2005;54 Suppl 4:iv1-i16[PMID:15888809 DOI:10.1136/gut.2004.053314]
136 Banfield A,Green S,Ramage JK.Neuroendocrine tumour management:a team approach.Hosp Med 2005;66:37-42[PMID:15686165]
137 O'Grady JG.Treatment options for other hepatic malignancies.Liver Transpl 2000;6:S23-S29[PMID:11084081 DOI:10 .1053/jlts.2000.18687]
138 Pavel M,Baudin E,Couvelard A,Krenning E,berg K,Steinmüller T,Anlauf M,Wiedenmann B,Salazar R.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut,midgut,hindgut,and unknown primary.Neuroendocrinology 2012;95:157-176[PMID:22262022 DOI:10 .1159/000335597]
139 Le Treut YP,Grégoire E,Klempnauer J,Belghiti J,Jouve E,Lerut J,Castaing D,Soubrane O,Boillot O,Mantion G,Homayounfar K,Bustamante M,Azoulay D,Wolf P,Krawczyk M,Pascher A,Suc B,Chiche L,de Urbina JO,Mejzlik V,Pascual M,Lodge JP,Gruttadauria S,Paye F,Pruvot FR,Thorban S,Foss A,Adam R.Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection:a 213-case European liver transplant registry study.Ann Surg 2013;257:807-815[PMID:23532105 DOI:10.1097/SLA.0b013e31828ee17c]
140 Gedaly R,Daily MF,Davenport D,McHugh PP,Koch A,Angulo P,Hundley JC.Liver transplantation for the treatment of liver metastases from neuroendocrine tumors:an analysis of the UNOS database.Arch Surg 2011;146:953-958[PMID:21844436 DOI:10.1001/archsurg.2011.186]
141 Nguyen NT,Harring TR,Goss JA,O’Mahony CA.Neuroendocrine Liver Metastases and Orthotopic Liver Transplantation:The US Experience.Int J Hepatol 2011;2011:742890[PMID:22254141 DOI:10.4061/2011/742890]
142 Le Treut YP,Grégoire E,Belghiti J,Boillot O,Soubrane O,Mantion G,Cherqui D,Castaing D,Ruszniewski P,Wolf P,Paye F,Salame E,Muscari F,Pruvot FR,Baulieux J.Predictors of long-term survival after liver transplantation for metastatic endocrine tumors:an 85-case French multicentric report.Am J Transplant 2008;8:1205-1213[PMID:18444921DOI:10.1111/j.1600-6143.2008.02233.x]
143 van Vilsteren FG,Baskin-Bey ES,Nagorney DM,Sanderson SO,Kremers WK,Rosen CB,Gores GJ,Hobday TJ.Liver transplantation for gastroenteropancreatic neuroendocrine cancers:Defining selection criteria to improve survival.Liver Transpl 2006;12:448-456[PMID:16498656 DOI:10.1002/lt.20702]
144 Rosenau J,Bahr MJ,von Wasielewski R,Mengel M,Schmidt HH,Nashan B,Lang H,Klempnauer J,Manns MP,Boeker KH.Ki67,E-cadherin,and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors.Transplantation 2002;73:386-394[PMID:11884935]
145 Olausson M,Friman S,Herlenius G,Cahlin C,Nilsson O,Jansson S,Wngberg B,Ahlman H.Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors.Liver Transpl 2007;13:327-333[PMID:17318853DOI:10.1002/lt.21056]
146 Mazzaferro V,Pulvirenti A,Coppa J.Neuroendocrine tumors metastatic to the liver:how to select patients for liver transplantationJ Hepatol 2007;47:460-466[PMID:17697723DOI:10.1016/j.jhep.2007.07.004]
147 Hackl C,Gerken M,Loss M,Klinkhammer-Schalke M,Piso P,Schlitt HJ.A population-based analysis on the rate and surgical management of colorectal liver metastases in Southern Germany.Int J Colorectal Dis 2011;26:1475-1481[PMID:21748289 DOI:10.1007/s00384-011-1278-5]
148 Chapman WC.Liver transplantation for unresectable metastases to the liver:a new era in transplantation or a time for cautionAnn Surg 2013;257:816-817[PMID:23532106 DOI:10 .1097/SLA.0b013e3182908c8d]
149 Foss A,Adam R,Dueland S.Liver transplantation for colorectal liver metastases:revisiting the concept.Transpl Int 2010;23:679 -685[PMID:20477993 DOI:10.1111/j.1432-2277.2010.01097.x]
150 Hagness M,Foss A,Line PD,Scholz T,Jrgensen PF,Fosby B,Boberg KM,Mathisen O,Gladhaug IP,Egge TS,Solberg S,Hausken J,Dueland S.Liver transplantation for nonresectable liver metastases from colorectal cancer.Ann Surg 2013;257:800 -806[PMID:23360920 DOI:10.1097/SLA.0b013e3182823957]
151 Andersen MH,Dueland S,Hagness M,Vidnes T,Finstad ED,Wahl AK,Foss A.Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma.Scand J Caring Sci 2012;26:713-719[PMID:22452269 DOI:10.1111/j.1471-6712.2012.00984.x]
152 Uskudar O,Raja K,Schiano TD,Fiel MI,del Rio Martin J,Chang C.Liver transplantation is possible in some patients with liver metastasis of colon cancer.Transplant Proc 2011;43 :2070-2074[PMID:21693328 DOI:10.1016/j.transproceed.2011.03.052]
153 Bachir NM,Larson AM.Adult liver transplantation in the United States.Am J Med Sci 2012;343:462-469[PMID:22683615DOI:10.1097/MAJ.0b013e3182308b66]
2 Jones PD,Hayashi PH,Barritt S.Liver transplantation in2013:challenges and controversies.Minerva Gastroenterol Dietol 2013;59:117-131[PMID:23831904]
3 Kim WR,Therneau TM,Benson JT,Kremers WK,Rosen CB,Gores GJ,Dickson ER.Deaths on the liver transplant waiting list:an analysis of competing risks.Hepatology 2006;43:345 -351[PMID:16440361 DOI:10.1002/hep.21025]
4 Malinchoc M,Kamath PS,Gordon FD,Peine CJ,Rank J,ter Borg PC.A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts.Hepatology 2000;31:864-871[PMID:10733541 DOI:10.1053/he.2000.5852]
5 Said A,Williams J,Holden J,Remington P,Gangnon R,Musat A,Lucey MR.Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease.J Hepatol 2004;40:897-903[PMID:15158328 DOI:10.1016/j.jhep.2004.02.010]
6 Weismüller TJ,Negm A,Becker T,Barg-Hock H,Klempnauer J,Manns MP,Strassburg CP.The introduction ofMELD-based organ allocation impacts 3-month survival after liver transplantation by influencing pretransplant patient characteristics.Transpl Int 2009;22:970-978[PMID:19619170DOI:10.1111/j.1432-2277.2009.00915.x]
7 Lee SG,Moon DB.Living donor liver transplantation for hepatocellular carcinoma.Recent Results Cancer Res 2013;190:165 -179[PMID:22941020 DOI:10.1007/978-3-642-16037-0_11]
8 Moon DB,Lee SG,Hwang S,Kim KH,Ahn CS,Ha TY,Song GW,Jung DH,Park GC,Namkoong JM,Park HW,Park YH,Park CS.More than 300 consecutive living donor liver transplants a year at a single center.Transplant Proc 2013;45:1942-1947[PMID:23769079 DOI:10.1016/j.transproceed.2013.02.041]
9 Song GW,Lee SG,Hwang S,Ahn CS,Moon DB,Kim KH,Ha TY,Jung DH,Park GC,Namgung JM,Park CS,Park HW,Park YH.Successful experiences of ABO-incompatible adult living donor liver transplantation in a single institute:no immunological failure in 10 consecutive cases.Transplant Proc2013;45:272-275[PMID:23375314 DOI:10.1016/j.transprocee d.2012.06.079]
10 Starzl TE.The long reach of liver transplantation.Nat Med2012;18:1489-1492[PMID:23042359 DOI:10.1038/nm.2927]
11 Starzl TE,Marchioro TL,Vonkaulla KN,Hermann G,Brittain RS,Waddell WR.Homotransplantation of the liver in humans.Surg Gynecol Obstet 1963;117:659-676[PMID:14100514]
12 Starzl TE,Groth CG,Brettschneider L,Penn I,Fulginiti VA,Moon JB,Blanchard H,Martin AJ,Porter KA.Orthotopic homotransplantation of the human liver.Ann Surg 1968;168:392 -415[PMID:4877589 DOI:10.1097/00007890-196709000-00033]
13 Shapiro HA.Brain death and organ transplantation.J Forensic Med 1968;15:89-90[PMID:5729525]
14 Starzl TE,Iwatsuki S,Klintmalm G,Schrter GP,Weil R,Koep LJ,Porter KA.Liver transplantation,1980,with particular reference to cyclosporin-A.Transplant Proc 1981;13:281 -285[PMID:7022839]
15 Starzl TE,Klintmalm GB,Porter KA,Iwatsuki S,Schrter GP.Liver transplantation with use of cyclosporin a and prednisone.N Engl J Med 1981;305:266-269[PMID:7017414DOI:10.1056/NEJM198107303050507]
16 National Institutes of Health Consensus Development Conference Statement:liver transplantation--June 20-23,1983.Hepatology 1984;4:107S-110S[PMID:6363254]
17 National Organ Transplant Act:Public Law 98-507.US Statut Large 1984;98:2339-2348[PMID:11660818]
18 Pichlmayr R,Ringe B,Gubernatis G,Hauss J,Bunzendahl H.[Transplantation of a donor liver to 2 recipients(splitting transplantation)--a new method in the further development of segmental liver transplantation].Langenbecks Arch Chir1988;373:127-130[PMID:3287073]
19 Broelsch CE,Emond JC,Whitington PF,Thistlethwaite JR,Baker AL,Lichtor JL.Application of reduced-size liver transplants as split grafts,auxiliary orthotopic grafts,and living related segmental transplants.Ann Surg 1990;212:368-375;discussion 375-377[PMID:2396888]
20 Bhangui P,Vibert E,Majno P,Salloum C,Andreani P,Zocrato J,Ichai P,Saliba F,Adam R,Castaing D,Azoulay D.Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma:living versus deceased donor transplantation.Hepatology 2011;53:1570-1579[PMID:21520172 DOI:10 .1002/hep.24231]
21 Gondolesi GE,Roayaie S,Muoz L,Kim-Schluger L,Schiano T,Fishbein TM,Emre S,Miller CM,Schwartz ME.Adult living donor liver transplantation for patients with hepatocellular carcinoma:extending UNOS priority criteria.Ann Surg 2004;239:142-149[PMID:14745320 DOI:10.1097/01.sla.0000109022.32391.eb]
22 Grant RC,Sandhu L,Dixon PR,Greig PD,Grant DR,McGilvray ID.Living vs.deceased donor liver transplantation for hepatocellular carcinoma:a systematic review and meta-analysis.Clin Transplant 2013;27:140-147[PMID:23157398DOI:10.1111/ctr.12031]
23 Kaihara S,Kiuchi T,Ueda M,Oike F,Fujimoto Y,Ogawa K,Kozaki K,Tanaka K.Living-donor liver transplantation for hepatocellular carcinoma.Transplantation 2003;75:S37-S40[PMID:12589138 DOI:10.1097/01.TP.0000047029.02806.16]
24 Sandhu L,Sandroussi C,Guba M,Selzner M,Ghanekar A,Cattral MS,McGilvray ID,Levy G,Greig PD,Renner EL,Grant DR.Living donor liver transplantation versus deceased donor liver transplantation for hepatocellular carcinoma:comparable survival and recurrence.Liver Transpl 2012;18:315 -322[PMID:22140013 DOI:10.1002/lt.22477]
25 Todo S,Furukawa H,Japanese Study Group on Organ Transplantation.Living donor liver transplantation for adult patients with hepatocellular carcinoma:experience in Japan.Ann Surg 2004;240:451-459;discussion 459-461[PMID:15319716 DOI:10.1097/01.sla.0000137129.98894.42]
26 Saidi RF,Jabbour N,Li Y,Shah SA,Bozorgzadeh A.Is left lobe adult-to-adult living donor liver transplantation ready for widespread useThe US experience(1998-2010).HPB(Oxford)2012;14:455-460[PMID:22672547 DOI:10.1111/j.1477-2574.2012.00475.x]
27 Saidi RF,Markmann JF,Jabbour N,Li Y,Shah SA,Cosimi AB,Bozorgzadeh A.The faltering solid organ donor pool in the United States(2001-2010).World J Surg 2012;36:2909-2913[PMID:22933050 DOI:10.1007/s00268-012-1748-0]
28 Muzaale AD,Dagher NN,Montgomery RA,Taranto SE,McBride MA,Segev DL.Estimates of early death,acute liver failure,and long-term mortality among live liver donors.Gastroenterology 2012;142:273-280[PMID:22108193 DOI:10 .1053/j.gastro.2011.11.015]
29 Roll GR,Roberts JP.Left versus right lobe liver donation.Am J Transplant 2014;14:251-252[PMID:24304562 DOI:10 .1111/ajt.12556]
30 Roll GR,Parekh JR,Parker WF,Siegler M,Pomfret EA,Ascher NL,Roberts JP.Left hepatectomy versus right hepatectomy for living donor liver transplantation:shifting the risk from the donor to the recipient.Liver Transpl 2013;19:472 -481[PMID:23447523 DOI:10.1002/lt.23608]
31 Ghobrial RM,Freise CE,Trotter JF,Tong L,Ojo AO,Fair JH,Fisher RA,Emond JC,Koffron AJ,Pruett TL,Olthoff KM.Donor morbidity after living donation for liver transplantation.Gastroenterology 2008;135:468-476[PMID:18505689DOI:10.1053/j.gastro.2008.04.018]
32 Geissler EK,Schlitt HJ.Immunosuppression for liver transplantation.Gut 2009;58:452-463[PMID:19052024 DOI:10 .1136/gut.2008.163527]
33 Sgourakis G,Radtke A,Fouzas I,Mylona S,Goumas K,Gockel I,Lang H,Karaliotas C.Corticosteroid-free immunosuppression in liver transplantation:a meta-analysis and meta-regression of outcomes.Transpl Int 2009;22:892-905[PMID:19453997 DOI:10 .1111/j.1432-2277.2009.00893.x]
34 Schlitt HJ,Jonas S,Ganten TM,Grannas G,Moench C,Rauchfuss F,Obed A,Tisone G,Pinna AD,Gerunda GE,Beckebaum S.Effects of mycophenolate mofetil introduction in liver transplant patients:results from an observational,non-interventional,multicenter study(LOBSTER).Clin Transplant 2013;27:368 -378[PMID:23405863 DOI:10.1111/ctr.12097]
35 Vivarelli M,Cucchetti A,Piscaglia F,La Barba G,Bolondi L,Cavallari A,Pinna AD.Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma:key role of immunosuppression.Liver Transpl 2005;11 :497-503[PMID:15838913 DOI:10.1002/lt.20391]
36 Farkas SA,Schnitzbauer AA,Kirchner G,Obed A,Banas B,Schlitt HJ.Calcineurin inhibitor minimization protocols in liver transplantation.Transpl Int 2009;22:49-60[PMID:19121146 DOI:10.1111/j.1432-2277.2008.00796.x]
37 Schnitzbauer AA,Zuelke C,Graeb C,Rochon J,Bilbao I,Burra P,de Jong KP,Duvoux C,Kneteman NM,Adam R,Bechstein WO,Becker T,Beckebaum S,Chazouillères O,CilloU,Colledan M,Fndrich F,Gugenheim J,Hauss JP,Heise M,Hidalgo E,Jamieson N,Knigsrainer A,Lamby PE,Lerut JP,Mkisalo H,Margreiter R,Mazzaferro V,Mutzbauer I,Otto G,Pageaux GP,Pinna AD,Pirenne J,Rizell M,Rossi G,Rostaing L,Roy A,Turrion VS,Schmidt J,Troisi RI,van Hoek B,Valente U,Wolf P,Wolters H,Mirza DF,Scholz T,Steininger R,Soderdahl G,Strasser SI,Jauch KW,Neuhaus P,Schlitt HJ,Geissler EK.A prospective randomised,open-labeled,trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma.BMC Cancer 2010;10:190[PMID:20459775 DOI:10.1186/1471-2407-10-190]
38 Guba M,von Breitenbuch P,Steinbauer M,Koehl G,Flegel S,Hornung M,Bruns CJ,Zuelke C,Farkas S,Anthuber M,Jauch KW,Geissler EK.Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor.Nat Med 2002;8:128 -135[PMID:11821896 DOI:10.1038/nm0202-128]
39 Shirouzu Y,Ryschich E,Salnikova O,Kerkadze V,Schmidt J,Engelmann G.Rapamycin inhibits proliferation and migration of hepatoma cells in vitro.J Surg Res 2010;159:705-713[PMID:19482307 DOI:10.1016/j.jss.2008.07.035]
40 Salvadori M.Antineoplastic effects of mammalian target of rapamycine inhibitors.World J Transplant 2012;2:74-83[PMID:24175199 DOI:10.5500/wjt.v2.i5.74]
41 Dahlke MH,Hoogduijn M,Eggenhofer E,Popp FC,Renner P,Slowik P,Rosenauer A,Piso P,Geissler EK,Lange C,Chabannes D,Mazzanti B,Bigenzahn S,Bertolino P,Kunter U,Introna M,Rambaldi A,Capelli C,Perico N,Casiraghi F,Noris M,Gotti E,Seifert M,Saccardi R,Verspaget HW,van Hoek B,Bartholomew A,Wekerle T,Volk HD,Remuzzi G,Deans R,Lazarus H,Schlitt HJ,Baan CC.Toward MSC in solid organ transplantation:2008 position paper of the MISOT study group.Transplantation 2009;88:614-619[PMID:19741455 DOI:10.1097/TP.0b013e3181b4425a]
42 Dillmann J,Popp FC,Fillenberg B,Zeman F,Eggenhofer E,Farkas S,Scherer MN,Koller M,Geissler EK,Deans R,Ladenheim D,Loss M,Schlitt HJ,Dahlke MH.Treatment-emergent adverse events after infusion of adherent stem cells:the MiSOT-I score for solid organ transplantation.Trials 2012;13 :211[PMID:23151227 DOI:10.1186/1745-6215-13-211]
43 Popp FC,Renner P,Eggenhofer E,Slowik P,Geissler EK,Piso P,Schlitt HJ,Dahlke MH.Mesenchymal stem cells as immunomodulators after liver transplantation.Liver Transpl2009;15:1192-1198[PMID:19790154 DOI:10.1002/lt.21862]
44 Parkin DM,Bray F,Ferlay J,Pisani P.Global cancer statistics,2002.CA Cancer J Clin 2005;55:74-108[PMID:15761078DOI:10.3322/canjclin.55.2.74]
45 Anthony PP.Hepatocellular carcinoma:an overview.Histopathology 2001;39:109-118[PMID:11493326 DOI:10.1046/j.1365-2559.2001.01188.x]
46 Block TM,Mehta AS,Fimmel CJ,Jordan R.Molecular viral oncology of hepatocellular carcinoma.Oncogene 2003;22:5093-5107[PMID:12910247 DOI:10.1038/sj.onc.1206557]
47 Gomaa AI,Khan SA,Toledano MB,Waked I,Taylor-Robinson SD.Hepatocellular carcinoma:epidemiology,risk factors and pathogenesis.World J Gastroenterol 2008;14:4300-4308[PMID:18666317 DOI:10.3748/wjg.14.4300]
48 Montalto G,Cervello M,Giannitrapani L,Dantona F,Terranova A,Castagnetta LA.Epidemiology,risk factors,and natural history of hepatocellular carcinoma.Ann N Y Acad Sci 2002;963 :13-20[PMID:12095924 DOI:10.1111/j.1749-6632.2002.tb04090.x]
49 Ringe B,Pichlmayr R,Wittekind C,Tusch G.Surgical treatment of hepatocellular carcinoma:experience with liver resection and transplantation in 198 patients.World J Surg1991;15:270-285[PMID:1851588 DOI:10.1007/BF01659064]
50 Iwatsuki S,Starzl TE,Sheahan DG,Yokoyama I,Demetris AJ,Todo S,Tzakis AG,Van Thiel DH,Carr B,Selby R.Hepatic resection versus transplantation for hepatocellularcarcinoma.Ann Surg 1991;214:221-228;discussion 228-229[PMID:1656903 DOI:10.1097/00000658-199109000-00005]
51 Yao FY,Ferrell L,Bass NM,Watson JJ,Bacchetti P,Venook A,Ascher NL,Roberts JP.Liver transplantation for hepatocellular carcinoma:expansion of the tumor size limits does not adversely impact survival.Hepatology 2001;33:1394-1403[PMID:11391528 DOI:10.1053/jhep.2001.24563]
52 Mazzaferro V,Regalia E,Doci R,Andreola S,Pulvirenti A,Bozzetti F,Montalto F,Ammatuna M,Morabito A,Gennari L.Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis.N Engl J Med 1996;334:693 -699[PMID:8594428 DOI:10.1056/NEJM199603143341104]
53 Mazzaferro V,Bhoori S,Sposito C,Bongini M,Langer M,Miceli R,Mariani L.Milan criteria in liver transplantation for hepatocellular carcinoma:an evidence-based analysis of 15years of experience.Liver Transpl 2011;17 Suppl 2:S44-S57[PMID:21695773 DOI:10.1002/lt.22365]
54 Dhir M,Lyden ER,Smith LM,Are C.Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma:a meta-analysis.HPB(Oxford)2012;14:635 -645[PMID:22882201 DOI:10.1111/j.1477-2574.2012.00500.x]
55 Earl TM,Chapman WC.Transplantation for hepatocellular carcinoma:the North American experience.Recent Results Cancer Res 2013;190:145-164[PMID:22941019 DOI:10.1007/978 -3-642-16037-0_10]
56 Yao FY.Liver transplantation for hepatocellular carcinoma:beyond the Milan criteria.Am J Transplant 2008;8:1982-1989[PMID:18727702 DOI:10.1111/j.1600-6143.2008.02351.x]
57 Belghiti J,Cortes A,Abdalla EK,Régimbeau JM,Prakash K,Durand F,Sommacale D,Dondero F,Lesurtel M,Sauvanet A,Farges O,Kianmanesh R.Resection prior to liver transplantation for hepatocellular carcinoma.Ann Surg 2003;238:885 -892;discussion 892-893[PMID:14631225 DOI:10.1097/01.sla.0000098621.74851.65]
58 Castroagudín JF,Delgado M,Villanueva A,Bustamante M,Martínez J,Otero E,ToméS,Martínez SM,Segade FR,Conde R,Dominguez-Muoz E,Varo E.Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates.Transplant Proc 2005;37:3871-3873[PMID:16386568 DOI:10 .1016/j.transproceed.2005.09.168]
59 Chua TC,Saxena A,Chu F,Morris DL.Hepatic resection for transplantable hepatocellular carcinoma for patients within Milan and UCSF criteria.Am J Clin Oncol 2012;35:141-145[PMID:21336092 DOI:10.1097/COC.0b013e318209ab7d]
60 Facciuto ME,Singh MK,Rochon C,Sharma J,Gimenez C,Katta U,Moorthy CR,Bentley-Hibbert S,Rodriguez-Davalos M,Wolf DC.Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis:evaluation of radiological and pathological response.J Surg Oncol 2012;105:692-698[PMID:21960321 DOI:10.1002/jso.22104]
61 Lu DS,Yu NC,Raman SS,Lassman C,Tong MJ,Britten C,Durazo F,Saab S,Han S,Finn R,Hiatt JR,Busuttil RW.Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.Hepatology 2005;41 :1130-1137[PMID:15841454 DOI:10.1002/hep.20688]
62 O'Connor JK,Trotter J,Davis GL,Dempster J,Klintmalm GB,Goldstein RM.Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation.Liver Transpl 2012;18:949-954[PMID:22467602 DOI:10.1002/lt.23439]
63 Pompili M,Mirante VG,Rondinara G,Fassati LR,Piscaglia F,Agnes S,Covino M,Ravaioli M,Fagiuoli S,Gasbarrini G,Rapaccini GL.Percutaneous ablation procedures in cirrhotic patients with hepatocellular carcinoma submitted to liver transplantation:Assessment of efficacy at explant analysis and of safety for tumor recurrence.Liver Transpl 2005;11:1117-1126[PMID:16123960 DOI:10.1002/lt.20469]
64 Poon RT,Fan ST,Lo CM,Liu CL,Wong J.Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function:implications for a strategy of salvage transplantation.Ann Surg 2002;235:373-382[PMID:11882759 DOI:10 .1097/00000658-200203000-00009]
65 Majno P,Lencioni R,Mornex F,Girard N,Poon RT,Cherqui D.Is the treatment of hepatocellular carcinoma on the waiting list necessaryLiver Transpl 2011;17 Suppl 2:S98-108[PMID:21954097 DOI:10.1002/lt.22391]
66 Yao FY,Bass NM,Nikolai B,Merriman R,Davern TJ,Kerlan R,Ascher NL,Roberts JP.A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma:implications for the current organ allocation policy.Liver Transpl 2003;9:684 -692[PMID:12827553 DOI:10.1053/jlts.2003.50147]
67 European Association For The Study Of The Liver,European Organisation For Research And Treatment Of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma.J Hepatol 2012;56:908-943[PMID:22424438 DOI:10.1016/j.jhep.2011.12.001]
68 Bharat A,Brown DB,Crippin JS,Gould JE,Lowell JA,Shenoy S,Desai NM,Chapman WC.Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival.J Am Coll Surg 2006;203:411-420[PMID:17000383 DOI:10.1016/j.jamcollsurg.2006.06.016]
69 Chan KM,Yu MC,Chou HS,Wu TJ,Lee CF,Lee WC.Significance of tumor necrosis for outcome of patients with hepatocellular carcinoma receiving locoregional therapy prior to liver transplantation.Ann Surg Oncol 2011;18:2638-2646[PMID:21584831 DOI:10.1245/s10434-011-1779-z]
70 Graziadei IW,Sandmueller H,Waldenberger P,Koenigsrainer A,Nachbaur K,Jaschke W,Margreiter R,Vogel W.Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome.Liver Transpl 2003;9:557 -563[PMID:12783395 DOI:10.1053/jlts.2003.50106]
71 Clavien PA,Lesurtel M,Bossuyt PM,Gores GJ,Langer B,Perrier A.Recommendations for liver transplantation for hepatocellular carcinoma:an international consensus conference report.Lancet Oncol 2012;13:e11-e22[PMID:22047762DOI:10.1016/S1470-2045(11)70175-9]
72 Mazzaferro V,Llovet JM,Miceli R,Bhoori S,Schiavo M,Mariani L,Camerini T,Roayaie S,Schwartz ME,Grazi GL,Adam R,Neuhaus P,Salizzoni M,Bruix J,Forner A,De Carlis L,Cillo U,Burroughs AK,Troisi R,Rossi M,Gerunda GE,Lerut J,Belghiti J,Boin I,Gugenheim J,Rochling F,Van Hoek B,Majno P.Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria:a retrospective,exploratory analysis.Lancet Oncol 2009;10:35 -43[PMID:19058754 DOI:10.1016/S1470-2045(08)70284-5]
73 Menon KV,Hakeem AR,Heaton ND.Meta-analysis:recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.Aliment Pharmacol Ther2013;37:411-419[PMID:23278125 DOI:10.1111/apt.12185]
74 El-Serag HB,Davila JA.Is fibrolamellar carcinoma different from hepatocellular carcinomaA US population-based study.Hepatology 2004;39:798-803[PMID:14999699 DOI:10 .1002/hep.20096]
75 Kakar S,Burgart LJ,Batts KP,Garcia J,Jain D,Ferrell LD.Clinicopathologic features and survival in fibrolamellar carcinoma:comparison with conventional hepatocellular carcinoma with and without cirrhosis.Mod Pathol 2005;18:1417-1423[PMID:15920538 DOI:10.1038/modpathol.3800449]
76 Pinna AD,Iwatsuki S,Lee RG,Todo S,Madariaga JR,Marsh JW,Casavilla A,Dvorchik I,Fung JJ,Starzl TE.Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation.Hepatology 1997;26:877-883[PMID:9328308 DOI:10 .1002/hep.510260412]
77 Stipa F,Yoon SS,Liau KH,Fong Y,Jarnagin WR,D’Angelica M,Abou-Alfa G,Blumgart LH,DeMatteo RP.Outcome of pa-tients with fibrolamellar hepatocellular carcinoma.Cancer 2006;106 :1331-1338[PMID:16475212 DOI:10.1002/cncr.21703]
78 El-Gazzaz G,Wong W,El-Hadary MK,Gunson BK,Mirza DF,Mayer AD,Buckels JA,McMaster P.Outcome of liver resection and transplantation for fibrolamellar hepatocellular carcinoma.Transpl Int 2000;13 Suppl 1:S406-S409[PMID:11112043 DOI:10.1007/s001470050372]
79 Bragazzi MC,Carpino G,Venere R,Semeraro R,Gentile R,Gaudio E,Alvaro,D.Cholangiocarcinoma:Epidemiology and risk factors.Transl.Gastrointest.Cancer 2012;1:21-32[DOI:10.3978/j.issn.2224-4778.2011.11.04]
80 Burke EC,Jarnagin WR,Hochwald SN,Pisters PW,Fong Y,Blumgart LH.Hilar Cholangiocarcinoma:patterns of spread,the importance of hepatic resection for curative operation,and a presurgical clinical staging system.Ann Surg 1998;228:385-394[PMID:9742921 DOI:10.1097/00000658-199809000-00011]
81 Choi SB,Kim KS,Choi JY,Park SW,Choi JS,Lee WJ,Chung JB.The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection:association of lymph node metastasis and lymph node dissection with survival.Ann Surg Oncol 2009;16:3048-3056[PMID:19626372DOI:10.1245/s10434-009-0631-1]
82 DeOliveira ML,Cunningham SC,Cameron JL,Kamangar F,Winter JM,Lillemoe KD,Choti MA,Yeo CJ,Schulick RD.Cholangiocarcinoma:thirty-one-year experience with 564patients at a single institution.Ann Surg 2007;245:755-762[PMID:17457168 DOI:10.1097/01.sla.0000251366.62632.d3]
83 Hemming AW,Reed AI,Fujita S,Foley DP,Howard RJ.Surgical management of hilar cholangiocarcinoma.Ann Surg2005;241:693-699;discussion 699-702[PMID:15849505 DOI:10 .1097/01.sla.0000160701.38945.82]
84 Wang Y,Li J,Xia Y,Gong R,Wang K,Yan Z,Wan X,Liu G,Wu D,Shi L,Lau W,Wu M,Shen F.Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy.J Clin Oncol 2013;31:1188-1195[PMID:23358969 DOI:10 .1200/JCO.2012.41.5984]
85 Pichlmayr R,Weimann A,Oldhafer KJ,Schlitt HJ,Klempnauer J,Bornscheuer A,Chavan A,Schmoll E,Lang H,Tusch G.Role of liver transplantation in the treatment of unresectable liver cancer.World J Surg 1995;19:807-813[PMID:8553670 DOI:10.1007/BF00299775]
86 Weimann A,Varnholt H,Schlitt HJ,Lang H,Flemming P,Hustedt C,Tusch G,Raab R.Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma.Br J Surg 2000;87:1182-1187[PMID:10971425 DOI:10.1046/j.1365-2168.2000.01532.x]
87 Rea DJ,Heimbach JK,Rosen CB,Haddock MG,Alberts SR,Kremers WK,Gores GJ,Nagorney DM.Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma.Ann Surg 2005;242 :451-458;discussion 458-461[PMID:16135931 DOI:10 .1097/01.sla.0000179678.13285.fa]
88 Rosen CB,Heimbach JK,Gores GJ.Surgery for cholangiocarcinoma:the role of liver transplantation.HPB(Oxford)2008;10:186-189[PMID:18773052 DOI:10.1080/13651820801992542]
89 Gu J,Bai J,Shi X,Zhou J,Qiu Y,Wu Y,Jiang C,Sun X,Xu F,Zhang Y,Ding Y.Efficacy and safety of liver transplantation in patients with cholangiocarcinoma:a systematic review and meta-analysis.Int J Cancer 2012;130:2155-2163[PMID:21387295 DOI:10.1002/ijc.26019]
90 Organ Procurement and Transplantation Network.Allocation of livers.Accessed 26 July 2013.Available from:URL:http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_8.pdf
91 Pandey D,Lee KH,Tan KC.The role of liver transplantation for hilar cholangiocarcinoma.Hepatobiliary Pancreat Dis Int2007;6:248-253[PMID:17548246]
92 Alvaro D,Cannizzaro R,Labianca R,Valvo F,Farinati F,Italian Society of Gastroenterology(SIGE),Italian Associationof Hospital Gastroenterology(AIGO),Italian Association of Medical Oncology(AIOM),Italian Association of Oncological Radiotherapy(AIRO).Cholangiocarcinoma:A position paper by the Italian Society of Gastroenterology(SIGE),the Italian Association of Hospital Gastroenterology(AIGO),the Italian Association of Medical Oncology(AIOM)and the Italian Association of Oncological Radiotherapy(AIRO).Dig Liver Dis 2010;42:831-838[PMID:20702152 DOI:10.1016/j.dld.2010.06.005]
93 Axelrod D,Koffron A,Kulik L,Al-Saden P,Mulcahy M,Baker T,Fryer J,Abecassis M.Living donor liver transplant for malignancy.Transplantation 2005;79:363-366[PMID:15699771 DOI:10.1097/01.TP.0000151658.25247.C4]
94 Jonas S,Mittler J,Pascher A,Theruvath T,Thelen A,Klupp J,Langrehr JM,Neuhaus P.Extended indications in livingdonor liver transplantation:bile duct cancer.Transplantation 2005;80:S101-S104[PMID:16286884 DOI:10.1097/01.tp.0000187106.29908.2b]
95 Schüle S,Altendorf-Hofmann A,UteF,RauchfuF,Freesmeyer M,Knsel T,Dittmar Y,Settmacher U.Liver transplantation for hilar cholangiocarcinoma--a single-centre experience.Langenbecks Arch Surg 2013;398:71-77[PMID:23053456 DOI:10.1007/s00423-012-1007-8]
96 Weiss SW,Enzinger FM.Epithelioid hemangioendothelioma:a vascular tumor often mistaken for a carcinoma.Cancer1982;50:970-981[PMID:7093931 DOI:10.1002/1097-0142(19820901)50]
97 Ishak KG,Sesterhenn IA,Goodman ZD,Rabin L,Stromeyer FW.Epithelioid hemangioendothelioma of the liver:a clinicopathologic and follow-up study of 32 cases.Hum Pathol 1984;15:839-852[PMID:6088383 DOI:10.1016/S0046-8177(84)80145-8]
98 Marino IR,Todo S,Tzakis AG,Klintmalm G,Kelleher M,Iwatsuki S,Starzl TE,Esquivel CO.Treatment of hepatic epithelioid hemangioendothelioma with liver transplantation.Cancer 1988;62:2079-2084[PMID:3052779]
99 Hertl M,Cosimi AB.Liver transplantation for malignancy.Oncologist 2005;10:269-281[PMID:15821247 DOI:10.1634/theoncologist.10-4-269]
100 Rodriguez JA,Becker NS,O’Mahony CA,Goss JA,Aloia TA.Long-term outcomes following liver transplantation for hepatic hemangioendothelioma:the UNOS experience from1987 to 2005.J Gastrointest Surg 2008;12:110-116[PMID:17710508 DOI:10.1007/s11605-007-0247-3]
101 Makhlouf HR,Ishak KG,Goodman ZD.Epithelioid hemangioendothelioma of the liver:a clinicopathologic study of 137 cases.Cancer 1999;85:562-582[PMID:10091730 DOI:10 .1002/(SICI)1097-0142(19990201)85]
102 Mehrabi A,Kashfi A,Fonouni H,Schemmer P,Schmied BM,Hallscheidt P,Schirmacher P,Weitz J,Friess H,Buchler MW,Schmidt J.Primary malignant hepatic epithelioid hemangioendothelioma:a comprehensive review of the literature with emphasis on the surgical therapy.Cancer 2006;107:2108-2121[PMID:17019735 DOI:10.1002/cncr.22225]
103 Wang LR,Zhou JM,Zhao YM,He HW,Chai ZT,Wang M,Ji Y,Chen Y,Liu C,Sun HC,Wu WZ,Ye QH,Zhou J,Fan J,Tang ZY,Wang L.Clinical experience with primary hepatic epithelioid hemangioendothelioma:retrospective study of 33patients.World J Surg 2012;36:2677-2683[PMID:22890877DOI:10.1007/s00268-012-1714-x]
104 Lerut JP,Orlando G,Adam R,Schiavo M,Klempnauer J,Mirza D,Boleslawski E,Burroughs A,Sellés CF,Jaeck D,Pfitzmann R,Salizzoni M,Sderdahl G,Steininger R,Wettergren A,Mazzaferro V,Le Treut YP,Karam V.The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma:report of the European liver transplant registry.Ann Surg 2007;246:949-957;discussion 957[PMID:18043096 DOI:10.1097/SLA.0b013e31815c2a70]
105 Ben-Haim M,Roayaie S,Ye MQ,Thung SN,Emre S,Fishbein TA,Sheiner PM,Miller CM,Schwartz ME.Hepaticepithelioid hemangioendothelioma:resection or transplantation,which and whenLiver Transpl Surg 1999;5:526-531[PMID:10545542 DOI:10.1002/lt.500050612]
106 Grotz TE,Nagorney D,Donohue J,Que F,Kendrick M,Farnell M,Harmsen S,Mulligan D,Nguyen J,Rosen C,Reid-Lombardo KM.Hepatic epithelioid haemangioendothelioma:is transplantation the only treatment optionHPB(Oxford)2010;12:546 -553[PMID:20887322 DOI:10.1111/j.1477-2574.2010.00213.x]
107 Nudo CG,Yoshida EM,Bain VG,Marleau D,Wong P,Marotta PJ,Renner E,Watt KD,Deschênes M.Liver transplantation for hepatic epithelioid hemangioendothelioma:the Canadian multicentre experience.Can J Gastroenterol 2008;22 :821-824[PMID:18925305]
108 Madariaga JR,Marino IR,Karavias DD,Nalesnik MA,Doyle HR,Iwatsuki S,Fung JJ,Starzl TE.Long-term results after liver transplantation for primary hepatic epithelioid hemangioendothelioma.Ann Surg Oncol 1995;2:483-487[PMID:8591077 DOI:10.1007/BF02307080]
109 Yokoyama I,Todo S,Iwatsuki S,Starzl TE.Liver transplantation in the treatment of primary liver cancer.Hepatogastroenterology 1990;37:188-193[PMID:2160421]
110 Debre R,Mozziconacci P,Habib E,Habib R.[Hepatoblastoma:malignant tumor of the liver with embryonic cells].Arch Fr Pediatr 1954;11:1013-1034[PMID:13229384]
111 Grossman EJ,Millis JM.Liver transplantation for non-hepatocellular carcinoma malignancy:Indications,limitations,and analysis of the current literature.Liver Transpl 2010;16:930 -942[PMID:20677284 DOI:10.1002/lt.22106]
112 Meyers RL,Tiao GM,Dunn SP,Langham MR.Liver transplantation in the management of unresectable hepatoblastoma in children.Front Biosci(Elite Ed)2012;4:1293-1302[PMID:22201955 DOI:10.2741/E460]
113 Weksberg R,Shuman C,Smith AC.Beckwith-Wiedemann syndrome.Am J Med Genet C Semin Med Genet 2005;137C:12 -23[PMID:16010676 DOI:10.1002/ajmg.c.30058]
114 Siciliano M,De Candia E,Ballarin S,Vecchio FM,Servidei S,Annese R,Landolfi R,Rossi L.Hepatocellular carcinoma complicating liver cirrhosis in type IIIa glycogen storage disease.J Clin Gastroenterol 2000;31:80-82[PMID:10914784DOI:10.1097/00004836-200007000-00020]
115 McLaughlin CC,Baptiste MS,Schymura MJ,Nasca PC,Zdeb MS.Maternal and infant birth characteristics and hepatoblastoma.Am J Epidemiol 2006;163:818-828[PMID:16510543DOI:10.1093/aje/kwj104]
116 Maruyama K,Ikeda H,Koizumi T.Hepatoblastoma associated with trisomy 18 syndrome:a case report and a review of the literature.Pediatr Int 2001;43:302-305[PMID:11380930DOI:10.1046/j.1442-200x.2001.01380.x]
117 Giardiello FM,Petersen GM,Brensinger JD,Luce MC,Cayouette MC,Bacon J,Booker SV,Hamilton SR.Hepatoblastoma and APC gene mutation in familial adenomatous polyposis.Gut 1996;39:867-869[PMID:9038672]
118 Zimmermann A.The emerging family of hepatoblastoma tumours:from ontogenesis to oncogenesis.Eur J Cancer 2005;41:1503-1514[PMID:15982867 DOI:10.1016/j.ejca.2005.02.035]
119 Brown J,Perilongo G,Shafford E,Keeling J,Pritchard J,Brock P,Dicks-Mireaux C,Phillips A,Vos A,Plaschkes J.Pretreatment prognostic factors for children with hepatoblastoma--results from the International Society of Paediatric Oncology(SIOP)study SIOPEL 1.Eur J Cancer 2000;36:1418-1425[PMID:10899656 DOI:10.1016/S0959-8049(00)00074-5]
120 Zsíros J,Maibach R,Shafford E,Brugieres L,Brock P,Czauderna P,Roebuck D,Childs M,Zimmermann A,Laithier V,Otte JB,de Camargo B,MacKinlay G,Scopinaro M,Aronson D,Plaschkes J,Perilongo G.Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery:final results of the SIOPEL-3 HR study.J Clin Oncol 2010;28:2584-2590[PMID:20406943DOI:10.1200/JCO.2009.22.4857]
121 Browne M,Sher D,Grant D,Deluca E,Alonso E,Whitington PF,Superina RA.Survival after liver transplantation for hepatoblastoma:a 2-center experience.J Pediatr Surg 2008;43:1973-1981[PMID:18970927 DOI:10.1016/j.jpedsurg.2008.05.031]
122 Faraj W,Dar F,Marangoni G,Bartlett A,Melendez HV,Hadzic D,Dhawan A,Mieli-Vergani G,Rela M,Heaton N.Liver transplantation for hepatoblastoma.Liver Transpl 2008;14 :1614-1619[PMID:18975296 DOI:10.1002/lt.21586]
123 Beaunoyer M,Vanatta JM,Ogihara M,Strichartz D,Dahl G,Berquist WE,Castillo RO,Cox KL,Esquivel CO.Outcomes of transplantation in children with primary hepatic malignancy.Pediatr Transplant 2007;11:655-660[PMID:17663690DOI:10.1111/j.1399-3046.2007.00751.x]
124 Avila LF,Luis AL,Hernandez F,Garcia Miguel P,Jara P,Andres AM,Lopez Santamaría M,Tovar JA.Liver transplantation for malignant tumours in children.Eur J Pediatr Surg 2006;16:411 -414[PMID:17211789 DOI:10.1055/s-2006-924730]
125 Austin MT,Leys CM,Feurer ID,Lovvorn HN,O’Neill JA,Pinson CW,Pietsch JB.Liver transplantation for childhood hepatic malignancy:a review of the United Network for Organ Sharing(UNOS)database.J Pediatr Surg 2006;41:182-186[PMID:16410130 DOI:10.1016/j.jpedsurg.2005.10.091]
126 Mejia A,Langnas AN,Shaw BW,Torres C,Sudan DL.Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center.Clin Transplant 2005;19:721-725[PMID:16313316 DOI:10.1111/j.1399-0012.2005.00410.x]
127 Kasahara M,Ueda M,Haga H,Hiramatsu H,Kobayashi M,Adachi S,Sakamoto S,Oike F,Egawa H,Takada Y,Tanaka K.Living-donor liver transplantation for hepatoblastoma.Am J Transplant 2005;5:2229-2235[PMID:16095502 DOI:10.1111/j.1600-6143.2005.01003.x]
128 Otte JB,Pritchard J,Aronson DC,Brown J,Czauderna P,Maibach R,Perilongo G,Shafford E,Plaschkes J,International Society of Pediatric Oncology(SIOP).Liver transplantation for hepatoblastoma:results from the International Society of Pediatric Oncology(SIOP)study SIOPEL-1 and review of the world experience.Pediatr Blood Cancer 2004;42:74 -83[PMID:14752798 DOI:10.1002/pbc.10376]
129 Molmenti EP,Wilkinson K,Molmenti H,Roden JS,Squires RH,Fasola CG,Tomlinson G,Nagata DE,D’Amico L,Lopez MJ,Savino LM,Marubashi S,Sanchez EQ,Goldstein RM,Levy MF,Andrews W,Andersen JA,Klintmalm GB.Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population.Am J Transplant 2002;2:535-538[PMID:12118897 DOI:10.1034/j.1600-6143.2002.20607.x]
130 Chardot C,Saint Martin C,Gilles A,Brichard B,Janssen M,Sokal E,Clapuyt P,Lerut J,Reding R,Otte JB.Living-related liver transplantation and vena cava reconstruction after total hepatectomy including the vena cava for hepatoblastoma.Transplantation 2002;73:90-92[PMID:11792985 DOI:10.1097/00007890-200201150-00017]
131 Reyes JD,Carr B,Dvorchik I,Kocoshis S,Jaffe R,Gerber D,Mazariegos GV,Bueno J,Selby R.Liver transplantation and chemotherapy for hepatoblastoma and hepatocellular cancer in childhood and adolescence.J Pediatr 2000;136:795-804[PMID:10839879 DOI:10.1016/S0022-3476(00)44469-0]
132 Tsoucalas G,Karamanou M,Androutsos G.The eminent German pathologist Siegfried Oberndorfer(1876-1944)and his landmark work on carcinoid tumors.Ann of Gastroenterol2011;24:98-100[PMID:24713679]
133 Toledo SP,Loureno DM,Toledo RA.A differential diagnosis of inherited endocrine tumors and their tumor counterparts.Clinics(Sao Paulo)2013;68:1039-1056[PMID:23917672 DOI:10.6061/clinics/2013(07)24]
134 Oberg K,Castellano D.Current knowledge on diagnosis and staging of neuroendocrine tumors.Cancer Metastasis Rev 2011;30 Suppl 1:3-7[PMID:21311954 DOI:10.1007/s10555-011-9292-1]
135 Ramage JK,Davies AH,Ardill J,Bax N,Caplin M,Grossman A,Hawkins R,McNicol AM,Reed N,Sutton R,Thakker R,Aylwin S,Breen D,Britton K,Buchanan K,Corrie P,Gillams A,Lewington V,McCance D,Meeran K,Watkinson A.Guidelines for the management of gastroenteropancreatic neuroendocrine(including carcinoid)tumours.Gut 2005;54 Suppl 4:iv1-i16[PMID:15888809 DOI:10.1136/gut.2004.053314]
136 Banfield A,Green S,Ramage JK.Neuroendocrine tumour management:a team approach.Hosp Med 2005;66:37-42[PMID:15686165]
137 O'Grady JG.Treatment options for other hepatic malignancies.Liver Transpl 2000;6:S23-S29[PMID:11084081 DOI:10 .1053/jlts.2000.18687]
138 Pavel M,Baudin E,Couvelard A,Krenning E,berg K,Steinmüller T,Anlauf M,Wiedenmann B,Salazar R.ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut,midgut,hindgut,and unknown primary.Neuroendocrinology 2012;95:157-176[PMID:22262022 DOI:10 .1159/000335597]
139 Le Treut YP,Grégoire E,Klempnauer J,Belghiti J,Jouve E,Lerut J,Castaing D,Soubrane O,Boillot O,Mantion G,Homayounfar K,Bustamante M,Azoulay D,Wolf P,Krawczyk M,Pascher A,Suc B,Chiche L,de Urbina JO,Mejzlik V,Pascual M,Lodge JP,Gruttadauria S,Paye F,Pruvot FR,Thorban S,Foss A,Adam R.Liver transplantation for neuroendocrine tumors in Europe-results and trends in patient selection:a 213-case European liver transplant registry study.Ann Surg 2013;257:807-815[PMID:23532105 DOI:10.1097/SLA.0b013e31828ee17c]
140 Gedaly R,Daily MF,Davenport D,McHugh PP,Koch A,Angulo P,Hundley JC.Liver transplantation for the treatment of liver metastases from neuroendocrine tumors:an analysis of the UNOS database.Arch Surg 2011;146:953-958[PMID:21844436 DOI:10.1001/archsurg.2011.186]
141 Nguyen NT,Harring TR,Goss JA,O’Mahony CA.Neuroendocrine Liver Metastases and Orthotopic Liver Transplantation:The US Experience.Int J Hepatol 2011;2011:742890[PMID:22254141 DOI:10.4061/2011/742890]
142 Le Treut YP,Grégoire E,Belghiti J,Boillot O,Soubrane O,Mantion G,Cherqui D,Castaing D,Ruszniewski P,Wolf P,Paye F,Salame E,Muscari F,Pruvot FR,Baulieux J.Predictors of long-term survival after liver transplantation for metastatic endocrine tumors:an 85-case French multicentric report.Am J Transplant 2008;8:1205-1213[PMID:18444921DOI:10.1111/j.1600-6143.2008.02233.x]
143 van Vilsteren FG,Baskin-Bey ES,Nagorney DM,Sanderson SO,Kremers WK,Rosen CB,Gores GJ,Hobday TJ.Liver transplantation for gastroenteropancreatic neuroendocrine cancers:Defining selection criteria to improve survival.Liver Transpl 2006;12:448-456[PMID:16498656 DOI:10.1002/lt.20702]
144 Rosenau J,Bahr MJ,von Wasielewski R,Mengel M,Schmidt HH,Nashan B,Lang H,Klempnauer J,Manns MP,Boeker KH.Ki67,E-cadherin,and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors.Transplantation 2002;73:386-394[PMID:11884935]
145 Olausson M,Friman S,Herlenius G,Cahlin C,Nilsson O,Jansson S,Wngberg B,Ahlman H.Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors.Liver Transpl 2007;13:327-333[PMID:17318853DOI:10.1002/lt.21056]
146 Mazzaferro V,Pulvirenti A,Coppa J.Neuroendocrine tumors metastatic to the liver:how to select patients for liver transplantationJ Hepatol 2007;47:460-466[PMID:17697723DOI:10.1016/j.jhep.2007.07.004]
147 Hackl C,Gerken M,Loss M,Klinkhammer-Schalke M,Piso P,Schlitt HJ.A population-based analysis on the rate and surgical management of colorectal liver metastases in Southern Germany.Int J Colorectal Dis 2011;26:1475-1481[PMID:21748289 DOI:10.1007/s00384-011-1278-5]
148 Chapman WC.Liver transplantation for unresectable metastases to the liver:a new era in transplantation or a time for cautionAnn Surg 2013;257:816-817[PMID:23532106 DOI:10 .1097/SLA.0b013e3182908c8d]
149 Foss A,Adam R,Dueland S.Liver transplantation for colorectal liver metastases:revisiting the concept.Transpl Int 2010;23:679 -685[PMID:20477993 DOI:10.1111/j.1432-2277.2010.01097.x]
150 Hagness M,Foss A,Line PD,Scholz T,Jrgensen PF,Fosby B,Boberg KM,Mathisen O,Gladhaug IP,Egge TS,Solberg S,Hausken J,Dueland S.Liver transplantation for nonresectable liver metastases from colorectal cancer.Ann Surg 2013;257:800 -806[PMID:23360920 DOI:10.1097/SLA.0b013e3182823957]
151 Andersen MH,Dueland S,Hagness M,Vidnes T,Finstad ED,Wahl AK,Foss A.Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma.Scand J Caring Sci 2012;26:713-719[PMID:22452269 DOI:10.1111/j.1471-6712.2012.00984.x]
152 Uskudar O,Raja K,Schiano TD,Fiel MI,del Rio Martin J,Chang C.Liver transplantation is possible in some patients with liver metastasis of colon cancer.Transplant Proc 2011;43 :2070-2074[PMID:21693328 DOI:10.1016/j.transproceed.2011.03.052]
153 Bachir NM,Larson AM.Adult liver transplantation in the United States.Am J Med Sci 2012;343:462-469[PMID:22683615DOI:10.1097/MAJ.0b013e3182308b66]